Drug product (DP) is the finished dosage form administered to patients, directly determining clinical safety and efficacy. Injectable DP release requires core tests: sterility, endotoxin, particulates, container closure integrity, pH, and potency. Products must be essentially free of visible particulates.
Release testing varies by dosage form: lyophilized powders need residual moisture and reconstitution time; liposomal formulations require encapsulation efficiency and particle size; prefilled syringes need silicone oil and glide force. Stability studies cover the product lifecycle from IND to commercial launch. Common risks include sterility failure, particulate failure, and container closure issues.
Creative Biogene provides a one-stop solution covering universal release tests, four dosage-form-specific modules, and stability studies – from IND submission to commercial launch.
| Test Category | Test Item | Core | Advanced | Rapid |
| Safety | Sterility (membrane filtration/direct inoculation) | ✓ | ✓ | ✓ (qPCR screen*) |
| Endotoxin | ✓ | ✓ | ✓ | |
| Sub-visible particulates | ✓ | ✓ | ✓ | |
| Visible particulates | ✓ | ✓ | ✓ | |
| Physicochemical | Fill volume/content uniformity (HPLC) | ✓ | ✓ | ✓ |
| pH, osmolality, appearance | ✓ | ✓ | ✓ | |
| Lyophilized | Residual moisture, reconstitution time | ✓ | ✓ | — |
| Liposomal | Encapsulation efficiency | — | ✓ | — |
| Particle size (DLS), zeta potential | — | ✓ | ✓ | |
| Nanoformulation | Particle size (DLS, PDI) | — | ✓ | ✓ |
| Drug loading, particle concentration | — | ✓ | — | |
| Prefilled syringe | Silicone oil, glide force | — | ✓ | — |
| Needle shield integrity (CCIT) | ✓ | ✓ | — | |
| Stability | Long-term (2-8°C / 25°C) | ✓ | ✓ | — |
| Accelerated (40°C) | — | ✓ | ✓ | |
| Forced degradation (heat/light/oxidation/pH/freeze✓thaw) | — | ✓ | — | |
| Photostability (ICH Q1B) | — | ✓ | — | |
| In-use stability | — | ✓ | — |
Based on systematic interpretation of USP general chapters for injectables and the ICH stability guideline series (Q1A–Q1F, Q5C, and the 2025 draft consolidation, which includes an ATMP annex), we have structured DP release and stability testing as an integrated workflow: universal release testing matrix → dosage form specific modules → stability study protocols → submission ready data delivery.
Compliance Framework
USP <1> Injections serves as the core quality framework, covering sterility (<71>), endotoxin (<85>/<86>), particulates (<788>/<790>), container-closure integrity (<1207>), pH (<791>), content uniformity (<905>), and extractables/leachables assessment (<1663>/<1664>). ICH stability guidelines provide the basis for protocol design. Our facility operates in compliance with GMP principles; data management follows ALCOA+ principles and 21 CFR Part 11, with full LIMS traceability and independent QA review per batch.
Universal Release Testing Matrix
Tests common to all injectable/liquid/liposomal/lyophilized dosage forms:
| Test | Method |
| Sterility | Membrane filtration or direct inoculation, 14-day incubation |
| Endotoxin | Kinetic chromogenic or recombinant factor C |
| Sub-visible particulates | Light obscuration or microscopy |
| Visible particulates | Light inspection |
| Fill volume/content uniformity | HPLC |
| pH | pH meter |
| Osmolality | Osmometer |
| Appearance | Visual inspection |
All methods are validated per GMP and ICH Q2 requirements.
Dosage-Form Specific Testing Modules
| Dosage Form | Key Tests |
| Lyophilized | Residual moisture, reconstitution time, and cake appearance |
| Liposomal | Encapsulation efficiency, particle size by DLS, zeta potential |
| Nanoformulation | Particle size by DLS, drug loading by HPLC, particle concentration by nanoparticle tracking analysis (NTA) |
| Prefilled syringe | Silicone oil residue, needle shield integrity, glide force |
Stability Study Protocols
We customize stability study protocols per ICH Q1A(R2) (2025 draft, under public consultation), covering long-term, accelerated, intermediate, forced degradation, and photostability studies. Study conditions, timepoints, and duration are tailored to your product type and submission stage. Test methods reuse DP/DS release assays.
Submission-Ready Reporting
Reports include method validation, stability protocols, timepoint data, statistical shelf-life analysis (ICH Q1E), and compliance statements – ready for direct inclusion in the "drug product release testing" and "stability studies" sections of CMC documentation.
| Platform | Key Equipment / Capability | Description |
| Microbiology | BSC, multi-zone incubators, sterility isolator, automated colony counter | Sterility (14-day incubation), endotoxin, bioburden |
| Particle & Appearance | Light obscuration counter, microscopy, inspection booth, AQL system | Sub-visible and visible particulates |
| Chromatography | HPLC/UPLC, LC-MS/MS | Assay/potency, content uniformity, impurity, drug loading |
| Physicochemical | pH meter, osmometer, UV/BCA, Karl Fischer titrator | pH, osmolality, concentration, residual moisture |
| Biophysical | DLS, zeta potential analyzer, NTA | Particle size, PDI, zeta potential, particle concentration |
| Container-Closure Integrity | Vacuum decay, pressure decay, high voltage, O2 headspace | Deterministic CCIT per USP <1207> |
| Prefilled Syringe | Tensile tester, IR, vacuum decay | Glide force, silicone oil, needle shield integrity |
| Stability Storage | Stability chambers, LN2, photostability chamber | All ICH conditions: IQ/OQ/PQ validated, 24/7 monitoring |
Encapsulation efficiency, particle size, and zeta potential per FDA guidance.
Residual moisture, reconstitution time, and cake appearance for freeze-dried injectables.
Particle size by DLS or NTA and drug loading by HPLC for nanomedicines.
Silicone oil residue, tip cap integrity, and glide force per USP 382.
Long-term, accelerated, forced degradation, photostability, and transport simulation.
For any uncertainty about dosage form specific testing (lyophilized moisture, liposomal encapsulation, prefilled syringe glide force, etc.), we design integrated strategies tailored to your product and regulatory pathway. Contact us for a customized DP release and stability plan.
Q1: What tests are mandatory for DP release? What is the difference between injectable and non-injectable products?
A: Per USP <1> Injections, injectable DP release must include sterility, endotoxin, sub-visible and visible particulates, container-closure integrity, pH, osmolality, fill volume/content uniformity, and appearance. USP <790> requires injectables to be "essentially free of visible particulates," with an AQL typically ≤0.65%. Non-injectables (e.g., oral, topical) have different requirements depending on dosage form and route of administration. Our technical team can provide a customized release testing plan based on your product type.
Q2: What is the acceptance criterion for residual moisture in lyophilized products? How is it tested?
A: Residual moisture is a critical CQA for lyophilized products. Excess moisture can degrade the active ingredient and collapse the cake. The industry's typical acceptance criterion is ≤1%, but the specific criterion should be product- and stability-data-based. Karl Fischer titration (USP <921> coulometric) is the gold standard. Our Core and Advanced packages both include residual moisture testing; the Advanced package adds reconstitution time and cake appearance assessment.
Q3: What special release tests are required for liposomal formulations?
A: Liposomal DP release requires additional focus on encapsulation efficiency, particle size distribution, and zeta potential. USP <729> specifies particle size testing for liposomal injectable emulsions: DLS or laser diffraction for mean particle size (intensity-weighted mean <500 nm), and light obscuration for tail large particles >5 μm. Encapsulation efficiency is commonly measured by ultracentrifugation, gel filtration, or column centrifugation (nPEC can achieve >90% separation efficiency for both lipophilic and hydrophilic drugs). The zeta potential absolute value is typically required to be ≥30 mV for colloidal stability. Our Advanced package provides a complete liposomal-specific testing panel.
Copyright © 2026 Creative Biogene. All rights reserved.